Weiss Ratings Reaffirms Sell (D-) Rating for Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Biopharma (NASDAQ:ABUS)‘s stock had its “sell (d-)” rating restated by research analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

ABUS has been the subject of several other reports. Wall Street Zen downgraded Arbutus Biopharma from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Chardan Capital reissued a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $4.36 on Friday. The stock has a market cap of $835.81 million, a PE ratio of -15.03 and a beta of 1.09. Arbutus Biopharma has a fifty-two week low of $2.70 and a fifty-two week high of $5.10. The firm’s 50-day simple moving average is $4.19 and its two-hundred day simple moving average is $3.61.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $10.74 million for the quarter, compared to analysts’ expectations of $2.21 million. Arbutus Biopharma had a negative return on equity of 59.28% and a negative net margin of 352.24%. Equities research analysts predict that Arbutus Biopharma will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Arbutus Biopharma

A number of hedge funds have recently added to or reduced their stakes in ABUS. Oxford Asset Management LLP bought a new stake in shares of Arbutus Biopharma in the second quarter worth $38,000. Daiwa Securities Group Inc. boosted its position in Arbutus Biopharma by 3,911.1% in the second quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 15,449 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Arbutus Biopharma by 71.5% during the 2nd quarter. Prudential Financial Inc. now owns 18,255 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 7,610 shares during the period. Los Angeles Capital Management LLC purchased a new stake in shares of Arbutus Biopharma during the 2nd quarter valued at about $61,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Arbutus Biopharma by 220.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 20,760 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 14,275 shares during the period. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.